Protocol for the Psychosis Immune Mechanism Stratified Medicine (PIMS) trial: a randomised double-blind placebo-controlled trial of single-dose tocilizumab in patients with psychosis
暂无分享,去创建一个
Jack C. Rogers | J. Suckling | G. Murray | N. Barnes | Martin Wilson | B. Deakin | R. Upthegrove | É. Foley | M. Kaser | G. Khandaker | S. Griffiths | D. Jadon | E. Warwick | F. Corsi-Zuelli | Alexander Murray | Hannah Hickinbotham
[1] C. Davatzikos,et al. Neurobiologically Based Stratification of Recent-Onset Depression and Psychosis: Identification of Two Distinct Transdiagnostic Phenotypes , 2022, Biological Psychiatry.
[2] John A. Williams,et al. Inflammation and Brain Structure in Schizophrenia and Other Neuropsychiatric Disorders , 2022, JAMA psychiatry.
[3] S. Wood,et al. Inflammation in first‐episode psychosis: The contribution of inflammatory biomarkers to the emergence of negative symptoms, a systematic review and meta‐analysis , 2022, Acta psychiatrica Scandinavica.
[4] N. Barnes,et al. T regulatory cells as a potential therapeutic target in psychosis? Current challenges and future perspectives , 2021, Brain, behavior, & immunity - health.
[5] Jack C. Rogers,et al. Oxidative Stress and the Pathophysiology and Symptom Profile of Schizophrenia Spectrum Disorders , 2021, Frontiers in Psychiatry.
[6] Peter B. Jones,et al. Associations of Immunological Proteins/Traits with Schizophrenia, Major Depression and Bipolar Disorder: A Bi-Directional Two-Sample Mendelian Randomization Study , 2021, Brain, Behavior, and Immunity.
[7] B. Deakin,et al. Impaired regulatory T cell control of astroglial overdrive and microglial pruning in schizophrenia , 2021, Neuroscience & Biobehavioral Reviews.
[8] C. Pariante,et al. The Role of Peripheral Inflammation in Clinical Outcome and Brain Imaging Abnormalities in Psychosis: A Systematic Review , 2021, Frontiers in Psychiatry.
[9] Jennifer M. Coughlin,et al. Meta-analysis of the Glial Marker TSPO in Psychosis Revisited: Reconciling Inconclusive Findings of Patient–Control Differences , 2020, Biological Psychiatry.
[10] Peter B. Jones,et al. Association between circulating levels of C-reactive protein and positive and negative symptoms of psychosis in adolescents in a general population birth cohort , 2020, Journal of psychiatric research.
[11] M. Nordentoft,et al. Efficacy and safety of anti-inflammatory agents in treatment of psychotic disorders – A comprehensive systematic review and meta-analysis , 2020, Brain, Behavior, and Immunity.
[12] R. Hinz,et al. Neuroinflammation as measured by positron emission tomography in patients with recent onset and established schizophrenia: implications for immune pathogenesis , 2020, Molecular Psychiatry.
[13] M. Boks,et al. The association between schizophrenia and the immune system: Review of the evidence from unbiased ‘omic-studies’ , 2020, Schizophrenia Research.
[14] R. Upthegrove,et al. Cytokines, Oxidative Stress and Cellular Markers of Inflammation in Schizophrenia. , 2019, Current topics in behavioral neurosciences.
[15] M. Davidson,et al. The effect of minocycline on symptoms in schizophrenia: Results from a randomized controlled trial , 2019, Schizophrenia Research.
[16] J. Costas,et al. Enrichment of rare genetic variants in astrocyte gene enriched co-expression modules altered in postmortem brain samples of schizophrenia , 2019, Neurobiology of Disease.
[17] Annie W Shieh,et al. Transcriptome-wide isoform-level dysregulation in ASD, schizophrenia, and bipolar disorder , 2018, Science.
[18] P. Pavlidis,et al. Transcriptomic evidence for alterations in astrocytes and parvalbumin interneurons in bipolar disorder and schizophrenia subjects , 2018, Biological Psychiatry.
[19] Peter B. Jones,et al. The benefit of minocycline on negative symptoms of schizophrenia in patients with recent-onset psychosis (BeneMin): a randomised, double-blind, placebo-controlled trial , 2018, The lancet. Psychiatry.
[20] F. Turkheimer,et al. Neuroinflammation in schizophrenia: meta-analysis of in vivo microglial imaging studies , 2018, Psychological Medicine.
[21] Jennifer M. Coughlin,et al. PET studies of the glial cell marker TSPO in psychosis patients - a meta-analysis using individual participant data , 2017, bioRxiv.
[22] C. Carter,et al. Cytokine alterations in first-episode schizophrenia and bipolar disorder: relationships to brain structure and symptoms , 2018, Journal of Neuroinflammation.
[23] B. Miller,et al. Meta-analysis of Cerebrospinal Fluid Cytokine and Tryptophan Catabolite Alterations in Psychiatric Patients: Comparisons Between Schizophrenia, Bipolar Disorder, and Depression , 2018, Schizophrenia bulletin.
[24] Peter B. Jones,et al. Association between a functional interleukin 6 receptor genetic variant and risk of depression and psychosis in a population-based birth cohort , 2017, Brain, Behavior, and Immunity.
[25] S. Horvath,et al. Shared molecular neuropathology across major psychiatric disorders parallels polygenic overlap , 2016, Science.
[26] Alan S. Brown,et al. A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Tocilizumab, An Interleukin-6 Receptor Antibody, For Residual Symptoms in Schizophrenia , 2017, Neuropsychopharmacology.
[27] R. Dantzer,et al. Immunopsychiatry: important facts , 2017, Psychological Medicine.
[28] R. Kahn,et al. Immune involvement in the pathogenesis of schizophrenia: a meta-analysis on postmortem brain studies , 2017, Translational Psychiatry.
[29] Brittany N. Lasseigne,et al. Post-mortem molecular profiling of three psychiatric disorders , 2016, bioRxiv.
[30] D. Goldsmith,et al. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression , 2016, Molecular Psychiatry.
[31] R. Mizrahi,et al. Postmortem evidence of cerebral inflammation in schizophrenia: a systematic review , 2016, Molecular Psychiatry.
[32] R. Dantzer,et al. Is there a role for immune-to-brain communication in schizophrenia? , 2016, Psychopharmacology.
[33] N. Tarrier,et al. Investigating the empirical support for therapeutic targets proposed by the temporal experience of pleasure model in schizophrenia: A systematic review , 2015, Schizophrenia Research.
[34] R. Murray,et al. Cortisol and Inflammatory Biomarkers Predict Poor Treatment Response in First Episode Psychosis , 2015, Schizophrenia bulletin.
[35] Peter B. Jones,et al. Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment. , 2015, The lancet. Psychiatry.
[36] Stefan Rose-John,et al. IL-6 biology: implications for clinical targeting in rheumatic disease , 2014, Nature Reviews Rheumatology.
[37] N. Barnes,et al. Cytokine function in medication-naive first episode psychosis: A systematic review and meta-analysis , 2014, Schizophrenia Research.
[38] N. Barnes,et al. The immune system and schizophrenia: An update for clinicians , 2014 .
[39] B. Miller,et al. C-reactive protein levels in schizophrenia: a review and meta-analysis. , 2014, Clinical schizophrenia & related psychoses.
[40] D. Rennie,et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. , 2013, Annals of internal medicine.
[41] D. F. Drake,et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. , 2013, JAMA psychiatry.
[42] Peter B. Jones,et al. Childhood infection and adult schizophrenia: A meta-analysis of population-based studies , 2012, Schizophrenia Research.
[43] G. Lewis,et al. Prenatal maternal infection, neurodevelopment and adult schizophrenia: a systematic review of population-based studies , 2012, Psychological Medicine.
[44] B. Kirkpatrick,et al. Meta-Analysis of Cytokine Alterations in Schizophrenia: Clinical Status and Antipsychotic Effects , 2011, Biological Psychiatry.
[45] Emmanuel Stip,et al. Inflammatory Cytokine Alterations in Schizophrenia: A Systematic Quantitative Review , 2008, Biological Psychiatry.
[46] Michael F. Green,et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. , 2007, Archives of general psychiatry.
[47] O. John,et al. Anticipatory and consummatory components of the experience of pleasure: A scale development study , 2006 .
[48] L. Clare,et al. A Meta-Analysis of Cognitive Deficits in Adults with a Diagnosis of Schizophrenia , 2005, Neuropsychology Review.
[49] R. Price,et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. , 2002, Arthritis and rheumatism.